China Biopharmaceutical Contract Manufacturing Market (2025-2030)

This research study extensively utilized secondary sources, directories, and databases to gather valuable information for analyzing the global biopharmaceutical contract manufacturing market. In-depth interviews were conducted with a variety of primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants. These interviews were essential for obtaining and verifying critical qualitative and quantitative information, as well as assessing the growth prospects of the market. The global market size estimated through secondary research was then validated and refined using inputs from primary research to determine the final market size.

Secondary Research

Secondary research was primarily utilized to gather information for a comprehensive study focused on the biopharmaceutical contract manufacturing market, emphasizing technical and commercial aspects. The sources consulted for this research included Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Bioprocess and Biosystems Engineering, Bioprocess International, PLOS Biology, European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Parenteral Drug Association (PDA), American Association of Pharmaceutical Scientists (AAPS), Global Cancer Observatory, American Chemical Society, National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), and World Journal of Pharmaceutical Sciences.

In addition to these sources, the study also included corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements. Other resources included business magazines, research journals, press releases, and information from trade, business, and professional associations, along with analyses from MarketsandMarkets. These sources were instrumental in acquiring essential information about key market players, classifications, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

Primary Research

After conducting an initial assessment of the global biopharmaceutical contract manufacturing market through secondary research, we carried out comprehensive primary research. This involved conducting in-depth interviews with experts from the demand side, including stakeholders from pharmaceutical and biotechnology companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), and academic and research institutions.

Additionally, we interviewed key supply-side participants, such as C-suite executives, senior executives, product managers, and marketing and sales leaders from leading manufacturers, distributors, and channel partners. Our research focused on six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts.

Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephone discussions to gain a comprehensive understanding of the market dynamics.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both bottom-up and top-down approaches were used to estimate and validate the total size of the biopharmaceutical contract manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

• A list of the major global players operating in the biopharmaceutical contract manufacturing market was generated.
• The revenues generated from their services have been determined through annual reports and secondary sources (including paid databases).
• The services were mapped according to market segments. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and industry experts.
• All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

Global Biopharmaceutical Contract Manufacturing Market Size: Bottom-up and Top-down Approach

Data Triangulation

After estimating the total market size, it was divided into several segments and subsegments. To refine the overall market analysis and obtain accurate statistics for each segment and subsegment, we employed data triangulation and market breakdown procedures wherever applicable. This involved studying various factors and trends from both the demand and supply sides to validate the findings.